New data showing physician confidence in DaTSCAN diagnostic tool presented at 2012 Movement Disorders Society Meeting
DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with Clinically Uncertain Parkinsonian Syndromes ("CUPS") as part of 1-year follow up from imaging at baseline versus no-imaging control group where DaTSCAN was collected at the study end.